Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade B 59.22 3.05% 1.75
BPMC closed up 3.05 percent on Monday, December 10, 2018, on 58 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BPMC trend table...

Date Alert Name Type % Chg
Dec 10 20 DMA Support Bullish 0.00%
Dec 7 20 DMA Support Bullish 3.05%
Dec 7 Down 3 Days in a Row Weakness 3.05%
Dec 6 20 DMA Support Bullish 1.60%
Dec 4 Bearish Engulfing Bearish 1.35%
Dec 4 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.35%
Dec 4 Multiple of Ten Bearish Other 1.35%
Dec 4 Outside Day Range Expansion 1.35%
Dec 3 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.77%
Dec 3 Crossed Above 20 DMA Bullish -1.77%

Older signals for BPMC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 109.0
52 Week Low 50.51
Average Volume 402,555
200-Day Moving Average 74.3219
50-Day Moving Average 63.3506
20-Day Moving Average 56.8225
10-Day Moving Average 57.74
Average True Range 3.5759
ADX 16.37
+DI 18.7982
-DI 20.743
Chandelier Exit (Long, 3 ATRs ) 57.51229999999999
Chandelier Exit (Short, 3 ATRs ) 61.2377
Upper Bollinger Band 61.8869
Lower Bollinger Band 51.7581
Percent B (%b) 0.74
BandWidth 17.825333
MACD Line -1.2891
MACD Signal Line -2.0634
MACD Histogram 0.7743
Fundamentals Value
Market Cap 2.32 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -18.98
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 64.37
Resistance 3 (R3) 63.91 61.73 63.51
Resistance 2 (R2) 61.73 60.42 61.96 63.22
Resistance 1 (R1) 60.48 59.61 61.11 60.94 62.94
Pivot Point 58.30 58.30 58.62 58.53 58.30
Support 1 (S1) 57.05 56.99 57.68 57.51 55.50
Support 2 (S2) 54.87 56.18 55.10 55.22
Support 3 (S3) 53.62 54.87 54.93
Support 4 (S4) 54.08